BOPI 09 BR/2023 REPERTOIRE NUMERIQUE 31 Figure 1 Consulter le mémoire (11) 21163 (51) A61K 31/5377(2018.01); A61K 31/706(2018.01); A61K 31/708(2018.01); A61P 35/00(2018.01) ; A61P 35/02(2018.01) (21) 1202300039 - PCT/EP2021/071368 (22) 30/07/2021 (30) US n° 63/059,419 du 31/07/2020; EP n° 20195633.1 du 11/09/2020 (54) Combination of a BCL-2 inhibitor and a hypomethylating agent for treating cancers, uses and pharmaceutical compositions thereof. (72) DESSEIN, Emmelyne (FR); MAHNKE, Lisa (US) et Michael Robert Cooper (US) (73) 1-LES LABORATOIRES SERVIER, 35 rue de Verdun, 92284 SURESNES cedex (FR) et 2-NOVARTIS AG, Lichtstrasse 35, 4056 BASEL (CH) (74) S.C.P AKKUM, AKKUM & Associates, n° 1777, Rue 6.261, Auditorium Jean Paul II, Quartier Mbankolo, B.P. 4966, YAOUNDE (CM). (57) A combination comprising a BCL-2 inhibitor with a hypomethylating agent, uses in the treatment of cancers and pharmaceutical compositions thereof. The Bcl-2 inhibitor is 5-(5-chloro-2-{[(31S)-3- (morpholin-4-ylmethyl)-3,4-dihydroisoquinolin2(1H)-yl]carbonyl}phenyl)-N-(5-cyano-1,2dimethyl-1H-pyrrol-3-yl)-N-(4-hydroxyphenyl)-1,2dimethyl-1H-pyrrole-3-carboxamide and the hypomethylating agent is selected from decitabine, azacitidine and guadecitabine.
RkJQdWJsaXNoZXIy MTM1NDc3MA==